Shares of Globus Medical (GMED) are set to plummet 18.41% in pre-market trading on Friday, following the release of disappointing first-quarter 2025 financial results and a reduced earnings outlook. The medical device maker's performance fell short of analyst expectations, raising concerns about its growth trajectory.

Globus Medical reported adjusted earnings per share (EPS) of $0.68 for Q1, missing the analyst consensus estimate of $0.74 by 8.11%. This represents a 5.56% decrease compared to the same period last year. The company's quarterly sales also disappointed, coming in at $598.12 million, 4.44% below the analyst consensus estimate. Adding to investor concerns, Globus Medical cut its full-year 2025 adjusted EPS outlook to a range of $3.00 to $3.30, down from the previous guidance of $3.10 to $3.40.

In response to the earnings miss and lowered outlook, several analysts have cut their target prices for Globus Medical stock. Wells Fargo reduced its target from $93 to $76, Jefferies from $105 to $90, and RBC from $101 to $95. Despite the setback, Globus Medical reaffirmed its full-year 2025 revenue guidance in the range of $2.80 billion to $2.90 billion. CEO Dan Scavilla cited softer deal closures, temporary integration-related supply-chain disruptions, and the timing of international distributor orders as factors impacting the company's recent performance.